Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.

abstract：:Lung cancer develops in a stepwise fashion, with an accumulation of molecular alterations progressing through preinvasive steps to invasive disease. This progression could be arrested or reversed through pharmacologic treatments, which are known as cancer chemoprevention. Preclinical and clinical findings relating to ...

journal_title：Expert review of anticancer therapy

authors： Cohen V,Khuri FR

更新日期：2005-06-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) patients with metastases limited in site and number, termed oligometastases, may represent a unique subpopulation of advanced NSCLC with improved prognosis. The optimal management of these patients remains unclear with the treatment approach currently undergoing a paradigm shift. The...

journal_title：Expert review of anticancer therapy

authors： Bergsma DP,Salama JK,Singh DP,Chmura SJ,Milano MT

更新日期：2015-01-01 00:00:00

abstract：:The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...

journal_title：Expert review of anticancer therapy

authors： Gore ME,Harrison ML,Montes A

更新日期：2007-01-01 00:00:00

abstract：:Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Alorabi M

更新日期：2015-01-01 00:00:00

abstract：:Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

journal_title：Expert review of anticancer therapy

authors： Onesti CE,Jerusalem G

更新日期：2020-12-13 00:00:00

abstract：:Total mesorectal excision has been established as a standard surgical procedure for rectal cancer. MRI is now routinely used for preoperative staging of rectal cancer and provides accurate assessment of the tumor relative to the circumferential margin, that is, the mesorectal fascia. This identifies patients at risk o...

journal_title：Expert review of anticancer therapy

authors： Jhaveri KS,Sadaf A

更新日期：2009-04-01 00:00:00

abstract：:Knowledge of the prognostic role of biomarkers in colorectal cancer is limited and the routine determination for clinical practice is not warranted. However, for some of these markers, data are promising enough for further evaluation. This review addresses a comprehensive analysis of prognostic biomarkers in colorecta...

journal_title：Expert review of anticancer therapy

authors： Graziano F,Catalano V,Baldelli AM,Cascinu S

更新日期：2001-08-01 00:00:00

abstract：:Background: Patients with metastatic renal cell carcinoma (mRCC) are commonly treated with tyrosine kinase inhibitors (TKIs). An adverse effect frequently suffered by patients is lethargy, which often leads to dose reduction or drug cessation. We aimed to assess whether hypogonadism is related to treatment with TKIs. ...

journal_title：Expert review of anticancer therapy

authors： Afshar M,Patel HRH,Jain A,Kumar A,Patel P,James ND,Porfiri E

更新日期：2019-06-01 00:00:00

abstract：:Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

journal_title：Expert review of anticancer therapy

authors： Surmont VF,van Meerbeeck JP

更新日期：2011-10-01 00:00:00

abstract：INTRODUCTION:Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell carcinoma and large-cell NE carcinoma. This classification is the current basis for orienting the daily practi...

journal_title：Expert review of anticancer therapy

authors： Metovic J,Barella M,Harari S,Pattini L,Albini A,Sonzogni A,Veronesi G,Papotti M,Pelosi G

更新日期：2020-12-24 00:00:00

abstract：:Gastrointestinal endoscopy and endoscopic ultrasound not only provide strategies to diagnose and stage malignancy, but also to administer palliative and definitive care. Options for anticancer therapy include endoscopic mucosal resection, photodynamic therapy, thermal therapy, self-expanding metal stents and recently,...

journal_title：Expert review of anticancer therapy

authors： Wong RF,Bhutani MS

更新日期：2005-08-01 00:00:00

abstract：:Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, having shown survival be...

journal_title：Expert review of anticancer therapy

authors： Birtle A

更新日期：2013-01-01 00:00:00

abstract：:With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

journal_title：Expert review of anticancer therapy

authors： Dixon JM

更新日期：2002-06-01 00:00:00

abstract：:For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

journal_title：Expert review of anticancer therapy

authors： Murawski N,Zwick C,Pfreundschuh M

更新日期：2010-03-01 00:00:00

abstract：:Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-D-glucose (FDG), which is an analog of glucose. The FDG uptake in cells is directly propor...

journal_title：Expert review of anticancer therapy

authors： Kumar R,Chauhan A,Vellimana AK,Chawla M

更新日期：2006-08-01 00:00:00

abstract：:It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...

journal_title：Expert review of anticancer therapy

authors： Ahmed M,Lalloo F,Evans DG

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:In the majority of cases, multiple myeloma is a disease occurring in elderly patients. In the last decades, a major improvement in myeloma patients' outcome has been achieved with the introduction of several new drugs. However, this positive outcome was less likely to occur in elderly patients. Areas cover...

journal_title：Expert review of anticancer therapy

authors： Salvini M,D'Agostino M,Bonello F,Boccadoro M,Bringhen S

更新日期：2018-09-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VEGFR signaling, the main regulator of this process, proved to be effecti...

journal_title：Expert review of anticancer therapy

authors： Battaglin F,Puccini A,Intini R,Schirripa M,Ferro A,Bergamo F,Lonardi S,Zagonel V,Lenz HJ,Loupakis F

更新日期：2018-03-01 00:00:00

abstract：:Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the...

journal_title：Expert review of anticancer therapy

authors： Mantovani G,Macciò A,Madeddu C,Massa E

更新日期：2003-06-01 00:00:00

abstract：:The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

journal_title：Expert review of anticancer therapy

authors： Greenberg CC,Bafford AC,Golshan M

更新日期：2008-02-01 00:00:00

abstract：:Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...

journal_title：Expert review of anticancer therapy

authors： Balk C,Witjes JA

更新日期：2004-08-01 00:00:00

abstract：:In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analo...

journal_title：Expert review of anticancer therapy

authors： Polastro L,Aftimos PG,Awada A

更新日期：2014-06-01 00:00:00

abstract：:Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

journal_title：Expert review of anticancer therapy

authors： Kelly C,Cassidy J

更新日期：2007-06-01 00:00:00

abstract：:Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

journal_title：Expert review of anticancer therapy

authors： Hussein MR,Baidas S

更新日期：2002-10-01 00:00:00

abstract：:Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air o...

journal_title：Expert review of anticancer therapy

authors： Taivans I,Bukovskis M,Strazda G,Jurka N

更新日期：2013-12-13 00:00:00

abstract：:Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improve...

journal_title：Expert review of anticancer therapy

authors： Maghami E,Kraus DH

更新日期：2004-06-01 00:00:00

abstract：:Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

journal_title：Expert review of anticancer therapy

authors： Jimeno A,Carducci M

更新日期：2005-06-01 00:00:00

abstract：INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

journal_title：Expert review of anticancer therapy

authors： Jullien M,Touzeau C,Moreau P

更新日期：2020-10-26 00:00:00

abstract：:Intensity-modulated radiation therapy (IMRT) represents a powerful advance in the planning and delivery of radiation therapy owing to its ability to deliver highly conformal treatment doses while sparing normal tissues. Dosimetric studies have shown the feasibility and theoretical benefit of treating with IMRT over 3D...

journal_title：Expert review of anticancer therapy

authors： Bockbrader M,Kim E

更新日期：2009-05-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00